Retractable Technologies (RVP) AI Stock Analysis

• Market Cap: $21.11M
• Dividend Yield: N/A
• Average Volume (3M): 43.58K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.57
• Revenue Growth: -16.05%
• EPS Growth: -195.28%
• Country: US
• Employees: 221
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.35
• Shares Outstanding: 29,937,159
• 10 Day Avg. Volume: 63,357
• 30 Day Avg. Volume: 43,578
• PEG Ratio: <0.01
• Price to Book (P/B): 0.26
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.62
• Enterprise Value/Market Cap: 0.81
• Enterprise Value/Revenue: 0.12
• Enterprise Value/Gross Profit: -5.81
• Enterprise Value/Ebitda: -3.18
• 1Y Price Target: $0.50
• Price Target Upside: -28.57% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 52 Neutral
• Price Target: $0.50 ▼(-28.57%Downside)

The overall stock score of 52 reflects financial distress and valuation concerns for Retractable Technologies. While technical indicators suggest some short-term positive momentum, the negative financial performance and lack of profitability significantly weigh down the score. Corporate events present a mixed picture, with operational challenges offset by shareholder confidence.

Retractable Technologies Business Overview & Revenue Model

Company Description

Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. It offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes. The company distributes its products through general line and specialty distributors, as well as through international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas.

How the Company Makes Money

Retractable Technologies, Inc. generates revenue primarily through the sale of its retractable safety syringe and blood collection products. The company's revenue model is based on direct sales to hospitals, clinics, and other healthcare facilities, as well as through distribution agreements with partners and distributors. Key revenue streams include the sale of its VanishPoint and Patient Safe product lines, which are utilized globally by healthcare professionals seeking to improve safety and compliance with needlestick prevention laws. Additionally, significant partnerships with government agencies and large healthcare organizations contribute to its earnings, as these entities often require bulk purchasing of medical safety devices.

Retractable Technologies Financial Statement Overview

Summary

The company is experiencing significant financial challenges with declining revenues and negative margins, indicating operational issues. Despite a stable balance sheet with low leverage, negative cash flows highlight liquidity concerns.

Income Statement

The revenue has shown a significant decline from 2021 to TTM (Trailing-Twelve-Months), dropping from $188M to $33.7M. The gross profit margin has turned negative in TTM, indicating cost issues or pricing pressures. Net and EBIT margins are also negative, highlighting ongoing profitability challenges. Despite previous profitability in 2021, the recent trend indicates financial distress.

Balance Sheet

The company's debt levels are low relative to equity, with a debt-to-equity ratio well under 1, indicating limited leverage risk. However, stockholders' equity has decreased over the periods, reflecting erosion of value. The equity ratio remains strong, suggesting a solid asset base relative to liabilities.

Cash Flow

The operating cash flow is negative in TTM, indicating the company is struggling to generate cash from operations. Free cash flow is also negative, reflecting challenges in maintaining liquidity. Historical free cash flow was volatile, and recent trends show deterioration, posing risks to financial stability.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	33.05M	43.60M	94.82M	188.38M	81.86M
Gross Profit	-1.03M	9.11M	28.25M	95.35M	37.01M
EBITDA	4.17M	-1.24M	9.94M	76.44M	27.17M
Net Income	-11.89M	-7.01M	5.08M	56.06M	24.22M
Balance Sheet
Total Assets	160.72M	179.67M	195.67M	206.30M	104.97M
Cash, Cash Equivalents and Short-Term Investments	44.56M	47.29M	49.38M	42.43M	25.65M
Total Debt	1.23M	1.54M	1.82M	2.10M	3.74M
Total Liabilities	73.55M	80.38M	89.13M	107.14M	55.09M
Stockholders Equity	87.17M	99.29M	106.54M	99.17M	49.88M
Cash Flow
Free Cash Flow	-13.00M	1.91M	-61.95K	-25.57M	-2.05M
Operating Cash Flow	-11.56M	2.77M	16.77M	32.79M	19.00M
Investing Cash Flow	3.66M	-10.76M	-31.20M	-63.04M	-19.33M
Financing Cash Flow	-535.43K	941.64K	4.99M	41.84M	11.96M

Retractable Technologies Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.70
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RVP, the sentiment is Positive. The current price of 0.7 is above the 20-day moving average (MA) of 0.66, above the 50-day MA of 0.67, and below the 200-day MA of 0.71, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 62.34 is Neutral, neither overbought nor oversold. The STOCH value of 59.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RVP.

Retractable Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MHUA	67 Neutral	$12.40M	1.07	7.10%	―	-0.19%	-18.41%
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%
RVP	52 Neutral	$21.11M	―	-25.89%	―	-16.05%	-195.28%
AKYA	49 Neutral	$64.44M	―	-354.27%	―	-14.55%	34.87%
FEMY	40 Neutral	$29.77M	―	-239.87%	―	61.97%	-6.89%
MLSS	40 Underperform	$46.69M	―	-88.36%	―	-9.13%	30.04%
STSS	―	$6.45M	―	-75.14%	―	―	―

Retractable Technologies Corporate Events

Retractable Technologies Reduces Manufacturing Workforce

On July 23, 2025, Retractable Technologies announced a reduction in its manufacturing workforce. This decision may impact the company’s operations and could have implications for its industry positioning and stakeholders.

Retractable Technologies Settles Lawsuit with Locke Lord LLP

On May 19, 2025, Retractable Technologies, Inc. entered into a Settlement Agreement resolving all claims in a lawsuit against Locke Lord LLP in the 44th District Court of Dallas County, Texas. The lawsuit involved allegations related to legal representation in previous litigation against Becton, Dickinson and Company. The settlement results in Retractable Technologies receiving $1.9 million, dismissing all claims with prejudice, and exchanging mutual releases with the defendants, with no admission of liability or damages by either party.

Retractable Technologies Holds Successful Shareholder Meeting

During the virtual Annual Meeting of Shareholders on May 9, 2025, Retractable Technologies, Inc. successfully elected three Class 1 directors and obtained shareholder approval for executive compensation. Additionally, shareholders decided that future advisory votes on executive compensation will occur every three years, aligning with the company’s strategic governance practices. These decisions are likely to impact the company’s operational governance and reflect shareholder confidence in the current management and strategic direction.